Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

GlobeNewsWire • Feb 18, 2026

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

KROS investors eye pipeline updates as rinvatercept advances in DMD and Takeda-backed elritercept hits milestones ahead of Q4 results.

Zacks Investment Research • Feb 18, 2026

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with disorders caused by abnormal signaling within the transforming growth factor-beta (TGF-β) protein family.

Zacks Investment Research • Jan 27, 2026

Is KROS' KER-065 the Next Breakthrough in DMD Space?

KROS is advancing KER-065 for Duchenne muscular dystrophy, with orphan drug status and a phase II trial planned for early 2026.

Zacks Investment Research • Jan 26, 2026

Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?

Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.

Zacks Investment Research • Jan 16, 2026

KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?

KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.

Zacks Investment Research • Jan 15, 2026

5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close

AES, BWA, ENS, PCG and KROS screen as low P/B stocks with Buy ratings, offering value-focused opportunities as 2025 comes to a close.

Zacks Investment Research • Dec 31, 2025

KROS or ARGX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Keros Therapeutics, Inc. (KROS) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Dec 30, 2025

Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher

Keros Therapeutics (KROS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research • Dec 22, 2025

Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why

Keros Therapeutics (KROS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Dec 22, 2025